| Metric | Value | Detail |
|---|---|---|
| Revenue | $14.3B | +1.0% YoY |
| Net income | $4.5B | 31.4% margin |
| Gross margin | n/a | Gross profit / revenue |
| Operating margin | 24.9% | Operating income / revenue |
| Return on equity | 14% | Net income / equity |
| Return on assets | 11% | Net income / assets |
| Revenue growth (YoY) | +1.0% | FY2024 to FY2025 |
| Revenue 3-yr CAGR | +5.6% | Compound annual |
| Diluted EPS | $43.07 | FY2025 |
| Debt-to-equity | 0.06 | Long-term debt / equity |
| Current ratio | 4.13 | Current assets / liabilities |
| Cash & equivalents | $3.1B | Balance sheet |
| Total assets | $40.6B | FY2025 year-end |
| Shareholders’ equity | $31.3B | FY2025 year-end |
| Share price | $664.52 | Delayed · 2026-07-10 |
| Market cap | $62.4B | Price × shares outstanding |
| P/E ratio | 13.9 | Market cap / net income |
| P/S ratio | 4.4 | Market cap / revenue |
| Dividend yield | n/a | Dividend / price |
Stock fundamentals · FY2025 · SEC 10-K data
REGENERON PHARMACEUTICALS, INC. (REGN) stock fundamentals
REGENERON PHARMACEUTICALS, INC. (REGN) reported $14.3B in revenue and $4.5B in net income in fiscal 2025, a 31.4% net margin, per its latest SEC 10-K filing. It carries a market capitalization of about $62.4B at a delayed share price. It scores 62/100 on WealthyBud's Investor Score, ranking #25 of 100 covered companies. Score is research, not investment advice.
Revenue (FY2025)
$14.3B
▲ +1.0% YoY
Net income
$4.5B
31.4% net margin
Market cap
$62.4B
Price $664.52 · delayed
P/E ratio
13.9
Price / earnings
Return on equity
14%
Net income / equity
Investor Score
62/100
#25 of 100 covered
REGENERON PHARMACEUTICALS, INC. fundamentals at a glance
The table summarizes REGENERON PHARMACEUTICALS, INC.'s key financial figures for fiscal 2025 — revenue, profitability, returns, growth and balance-sheet strength — each taken from the company's SEC 10-K filing.
How profitable is REGENERON PHARMACEUTICALS, INC.?
REGENERON PHARMACEUTICALS, INC. runs a 31.4% net margin and n/a gross margin in fiscal 2025, turning $14.3B of revenue into $4.5B of profit. Return on equity is 14% and return on assets 11%.
Is REGENERON PHARMACEUTICALS, INC. growing?
REGENERON PHARMACEUTICALS, INC.'s revenue changed +1.0% in fiscal 2025 and compounded at +5.6% a year over three years, reaching $14.3B. Diluted earnings per share were $43.07 for the year.
| Fiscal year | Revenue | Growth |
|---|---|---|
| 2021 | $16.1B | n/a |
| 2022 | $12.2B | -24.3% |
| 2023 | $13.1B | +7.8% |
| 2024 | $14.2B | +8.3% |
| 2025 | $14.3B | +1.0% |
How is REGENERON PHARMACEUTICALS, INC. valued?
REGENERON PHARMACEUTICALS, INC. carries a market capitalization of $62.4B at a delayed share price of $664.52, trading at a 13.9 price-to-earnings ratio and 4.4 price-to-sales. Its Value subscore is 70/100 across the covered universe.
How financially healthy is REGENERON PHARMACEUTICALS, INC.?
REGENERON PHARMACEUTICALS, INC. ended fiscal 2025 with $3.1B in cash, a debt-to-equity ratio of 0.06 and a current ratio of 4.13. Lower leverage and a current ratio above 1.0 signal a stronger balance sheet.
What is REGENERON PHARMACEUTICALS, INC.'s Investor Score?
REGENERON PHARMACEUTICALS, INC. scores 62/100 on WealthyBud's Investor Score, #25 of 100 covered companies as of 2026-07-10. The score blends growth, profitability, returns on capital, balance-sheet strength and value into one percentile. It is a research opinion, not investment advice.
Investor Score
62/100
#25 of 100 covered companies
Subscores are percentile ranks (0–100) across the 100 covered companies, computed from the SEC fundamentals and delayed market price cited on this page. Data-derived opinion, not investment advice.
REGENERON PHARMACEUTICALS, INC. (REGN) stock FAQ
How much revenue does REGENERON PHARMACEUTICALS, INC. make?
REGENERON PHARMACEUTICALS, INC. (REGN) reported $14.3B in revenue in fiscal 2025, +1.0% versus the prior year, according to its SEC 10-K filing. Over the past three years its revenue has compounded at +5.6% a year.
Is REGENERON PHARMACEUTICALS, INC. profitable?
Yes. REGENERON PHARMACEUTICALS, INC. earned $4.5B in net income in fiscal 2025, a 31.4% net margin. Its return on equity was 14% and return on assets 11%, based on figures from its latest 10-K.
How fast is REGENERON PHARMACEUTICALS, INC. growing?
REGENERON PHARMACEUTICALS, INC.'s revenue changed +1.0% year over year in fiscal 2025 and compounded at +5.6% annually over three years. Growth is one of four inputs to its WealthyBud Investor Score, scored 41/100 versus the covered universe.
What is REGENERON PHARMACEUTICALS, INC.'s market cap and P/E ratio?
REGENERON PHARMACEUTICALS, INC. has a market capitalization of $62.4B at a delayed share price of $664.52, trading at a price-to-earnings ratio of 13.9 and price-to-sales of 4.4. Its dividend yield is n/a. Prices are delayed and illustrative.
What is REGENERON PHARMACEUTICALS, INC.'s WealthyBud Investor Score?
REGENERON PHARMACEUTICALS, INC. scores 62/100, ranking #25 of 100 covered companies as of 2026-07-10. The score is a percentile blend of growth (41), profitability (71), returns on capital (48), balance-sheet strength (96) and value (70). It is a research opinion, not investment advice.
Where does this REGENERON PHARMACEUTICALS, INC. financial data come from?
Fundamentals come from REGENERON PHARMACEUTICALS, INC.'s annual report (Form 10-K) filed with the SEC, via the public-domain EDGAR database. The share price used for market cap, P/E and yield is a delayed end-of-day quote, shown as illustrative; a production site would use a licensed real-time market-data feed.
Fundamentals are drawn from REGENERON PHARMACEUTICALS, INC.’s FY2025 Form 10-K filed with the
SEC (EDGAR, public domain), retrieved 2026-07-10. Share price is a delayed end-of-day quote; market cap, P/E, P/S
and dividend yield are illustrative and not real-time. The Investor Score is a data-derived research opinion.
Not investment advice.